uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
Go back to uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies| UNIQURE (NASDAQ: QURE) | Delayed: 49.04 +4.65 (10.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.39 | 52 Week High | $22.79 | |||
| Open | $44.47 | 52 Week Low | $6.63 | |||
| Day High | $49.58 | P/E | N/A | |||
| Day Low | $44.47 | EPS | $0.00 | |||
| Volume | 3,439,189 | |||||
